590 related articles for article (PubMed ID: 18822145)
1. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.
Eichelberger MC; Hassantoufighi A; Wu M; Li M
Virol J; 2008 Sep; 5():109. PubMed ID: 18822145
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
3. [Susceptibility of Influenza B Viruses to Neuraminidase Inhibitors Isolated during 2013-2014 Influenza Season in Mainland China].
Huang W; Li X; Tan M; Wei H; Cheng Y; Guo J; Wang Z; Xiao N; Wang D; Shu Y
Bing Du Xue Bao; 2015 Mar; 31(2):152-6. PubMed ID: 26164940
[TBL] [Abstract][Full Text] [Related]
4. A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis.
Martinez-Gil L; Alamares-Sapuay JG; Ramana Reddy MV; Goff PH; Premkumar Reddy E; Palese P
Antiviral Res; 2013 Oct; 100(1):29-37. PubMed ID: 23891991
[TBL] [Abstract][Full Text] [Related]
5. [Sensitivity of the epidemic and pandemic influenza virus strains to zanamivir (Relenze) in in vitro experiments].
L'vov DK; Burtseva EI; Galegov GA; Beliakova NV; Shevchenko ES; Kolobukhina LV; Merkulova LN; Prilipov AG; Leneva IA; Baranov NI; Gorelikov VN; Abramov DD
Vopr Virusol; 2010; 55(6):10-4. PubMed ID: 21381333
[TBL] [Abstract][Full Text] [Related]
6. Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.
Abed Y; Fage C; Lagüe P; Carbonneau J; Papenburg J; Vinh DC; Boivin G
Emerg Infect Dis; 2019 Apr; 25(4):838-840. PubMed ID: 30882323
[TBL] [Abstract][Full Text] [Related]
7. Baloxavir marboxil (Xofluza) for treatment of influenza.
Med Lett Drugs Ther; 2018 Dec; 60(1561):193-196. PubMed ID: 30653474
[No Abstract] [Full Text] [Related]
8. DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors.
Kožíšek M; Navrátil V; Rojíková K; Pokorná J; Berenguer Albiñana C; Pachl P; Zemanová J; Machara A; Šácha P; Hudlický J; Císařová I; Řezáčová P; Konvalinka J
Biochem J; 2018 Dec; 475(23):3847-3860. PubMed ID: 30404922
[TBL] [Abstract][Full Text] [Related]
9. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV
Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
[TBL] [Abstract][Full Text] [Related]
11. [Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
Huang L; Zhou JF; Wei H; Shu YL
Bing Du Xue Bao; 2012 Sep; 28(5):572-6. PubMed ID: 23233936
[TBL] [Abstract][Full Text] [Related]
12. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.
Deyde VM; Okomo-Adhiambo M; Sheu TG; Wallis TR; Fry A; Dharan N; Klimov AI; Gubareva LV
Antiviral Res; 2009 Jan; 81(1):16-24. PubMed ID: 18835410
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors.
Tisdale M
Rev Med Virol; 2000; 10(1):45-55. PubMed ID: 10654004
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of sialidase activity as a therapeutic approach.
Glanz VY; Myasoedova VA; Grechko AV; Orekhov AN
Drug Des Devel Ther; 2018; 12():3431-3437. PubMed ID: 30349196
[TBL] [Abstract][Full Text] [Related]
15. Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
Yamada H; Nagao C; Haredy AM; Mori Y; Mizuguchi K; Yamanishi K; Okamoto S
Antiviral Res; 2014 Nov; 111():69-77. PubMed ID: 25234090
[TBL] [Abstract][Full Text] [Related]
16. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
[TBL] [Abstract][Full Text] [Related]
17. [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
Reina J
Rev Esp Quimioter; 2006 Dec; 19(4):317-22. PubMed ID: 17235399
[No Abstract] [Full Text] [Related]
18. John F. Enders lecture 2006: antivirals for influenza.
Ong AK; Hayden FG
J Infect Dis; 2007 Jul; 196(2):181-90. PubMed ID: 17570104
[TBL] [Abstract][Full Text] [Related]
19. 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses.
Boechat Fda C; Sacramento CQ; Cunha AC; Sagrillo FS; Nogueira CM; Fintelman-Rodrigues N; Santos-Filho O; Riscado CS; Forezi Lda S; Faro LV; Brozeguini L; Marques IP; Ferreira VF; Souza TM; de Souza MC
Bioorg Med Chem; 2015 Dec; 23(24):7777-84. PubMed ID: 26643220
[TBL] [Abstract][Full Text] [Related]
20. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.
Ison MG; Gubareva LV; Atmar RL; Treanor J; Hayden FG
J Infect Dis; 2006 Mar; 193(6):760-4. PubMed ID: 16479508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
